/
Immunology
Vasculitis
24
Pipeline Programs↗
35
Active Trials↗
19
Companies Involved↗
Vasculitis is an emerging landscape with 24 programs across 19 companies. The most active players are Novartis, NovelMed Therapeutics, AstraZeneca. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 11
Phase 211
Phase 35
Approved
No programs
Analysis
Modality Breakdown
68%
Small molecule
15 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 92% of 24 pipeline programs.
Analysis
Trial Status
82
clinical trials
Completed26 · 32%
Recruiting19 · 23%
Active, not recruiting10 · 12%
Unknown status10 · 12%
Terminated8 · 10%
Not yet recruiting6 · 7%
Other3 · 4%
Clinical Trials
Trial Activity
82 trials
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)